Standard Biotools (LAB) Operating Leases (2019 - 2026)

Standard Biotools (LAB) has 8 years of Operating Leases data on file, last reported at $23.7 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 5.0% year-over-year to $23.7 million in Q1 2026; TTM through Mar 2026 was $23.7 million, a 5.0% decrease from a year earlier, with the FY2025 full-year figure at $25.0 million, down 2.16% from the prior year.
• Operating Leases for Q1 2026 stood at $23.7 million, down from $25.0 million in the prior quarter.
• Over the last five years, Operating Leases for LAB reached as high as $40.0 million in Q1 2022 and fell as low as $22.0 million in Q3 2025.
• Historically, Operating Leases has averaged $29.9 million across 5 years, with a median of $30.4 million in 2023.
• Across the five-year window, Operating Leases decreased 1.17% in 2022 and decreased 21.9% in 2025, its largest moves.
• Year by year, Operating Leases stood at $34.1 million in 2022, then decreased by 10.88% to $30.4 million in 2023, then declined by 15.75% to $25.6 million in 2024, then slipped by 2.16% to $25.0 million in 2025, then slipped by 5.54% to $23.7 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $23.7 million in Q1 2026, $25.0 million in Q4 2025, and $22.0 million in Q3 2025.